— Know what they know.
/
Not Investment Advice
Also trades as: 0IDA.L (LSE) · $vol 0M

DVAX NASDAQ

Dynavax Technologies Corporation
1W: +38.2% 1M: +43.6% 3M: +49.6% 1Y: +18.3% 3Y: +42.5% 5Y: +174.6%
$15.50
Last traded 2025-12-31 — delisted
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · $1.8B mcap · 100M float · 3.15% daily turnover · Short 43% of daily vol
Overview News Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings
Dividends Analysis Technicals Weather Peers ESG Institutions ETF Exposure Dark Pool Short Interest Supply Chain

Supply Chain Overview

1 relationships
0
As Filer
counterparties named
1
As Counterparty
mentioned by others
2025-11-05
Earliest Filing
2025-11-05
Latest Filing

Mentioned As Counterparty

1 mentions

Other companies that named DVAX in their SEC 8-K filings.

Filed By Relationship Summary Filing Date SEC
VXRT Vaxart, Inc. target Dynavax acquired an exclusive worldwide license to Vaxart's oral COVID-19 vaccine program and made an equity investment. 2025-11-05 View
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text. Covers 2021–2026. View on SEC EDGAR

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms